DESRIANI*1, RAMADHAN2 AND WIRSMA ARIEF HARAHAP3.
1Research Center For Biotechnology, Indonesian Institute of Sciences, Jl. Raya Bogor
Km 46, Kec. Cibinong, Kab. Bogor, 16911. Indonesia. Phone: +62-21-8754587. 2Division
of Surgical Oncology Dharmais Cancer Hospital, Jl. Letjend S. Parman No. 84-86 Slipi,
Jakarta Barat. Indonesia. 3Division of Surgical Oncology Medical School of Andalas
University -M.Djamil Hospital, Jl Perintis Kemerdekaan no 94, Padang. Indonesia.
Phone: +62-0751-31746.
ABSTRACT
Breast cancer is a deadly disease, occupied as first ranking among woman
patients cancer in Indonesia (the Hospital Information System, 2007). 20-30%
of total breast cancer patients having HER-2/neu overexpression. Unfortunately
the problem of resistance to monoclonal antibody treatment, trastuzumab,
was found. There are several theories that suspected as the cause of trastuzumab
resistence such as polimorphisme, receptor dysfunction and so on. Thisresearch
was conducted to study and to isolate of the HER-2/neu receptor gene in breast cancer
patients Indonesia. The successful of the HER-2/neu receptor gene issolation is an
important stage for the study and analysis of HER-2/neu receptor in Indonesia.
Research methods were breast cancer tissue collection from Dharmais Cancer Hospital
and M. Djamil Hospital Padang, RNA isolation, cDNA, PCR, sequencing. Of the total
110 samples, 20 samples of breast cancer patients identified as HER-2/neu+3 through
immunohistochemistry (IHC) screening. Of the 20 samples,4 DNA fragments (2127bp)
have successed isolated. This DNA fragment sequenced, then identified as a
gene encoding HER-2/neu receptor using BLAST. Due to the variation of HER-2/neu
overexpression in the tissue sample, while the part is taken as a source of RNA isolation
is only a little of it, the possibility to use of non HER-2/neu overexpression
part had a large, and other reason RNA low stability were also affected
to the success of a gene encoding HER-2/neu receptor issolation.
KEY WORDS: HER-2/neu Recepor gene, Breast Cancer, Trastuzumab, Resistance.
